Financial PerformanceMarch rebounded strongly and exceeded management expectations, with April tracking in line with expectations and a seasonally stronger Q2 anticipated.
Market OpportunityNew guidelines from the AAP now recommend exome/genome as a first-line test for kids with development delay & intellectual disability, opening a big opportunity for WGS to access general pediatricians.
Product InnovationThe ultra-rapid genome was launched in April, offering a fast turnaround time and competitive pricing, which may help take volumes from smaller competitors.